UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2196-15
Program Prior Authorization/Medical Necessity
Medication Cosentyx® (secukinumab) prefilled syringe or Sensoready pen
P&T Approval Date 5/2020, 7/2020, 11/2020, 6/2021, 7/2021, 12/2021, 2/2022, 3/2022,
6/2022, 11/2022, 1/2023, 4/2023, 7/2023, 1/2024, 10/2024
Effective Date 1/1/2025
1. Background:
Cosentyx (secukinumab) is a human interleukin-17A antagonist indicated for the treatment of
moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic
therapy or phototherapy, active psoriatic arthritis (PsA) in patients 2 years of age and older, adults
with active ankylosing spondylitis (AS) or active non-radiographic axial spondyloarthritis (nr-
axSpA) with objective signs of inflammation, active enthesitis-related arthritis (ERA) in patients
4 years of age and older, and adults with moderate to severe hidradenitis (HS).
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Cosentyx will be approved based on all of the following criteria:
(1) Diagnosis of moderate to severe plaque psoriasis
-AND-
(2) One of the following:
(a) All of the following:
i. Greater than or equal to 3% body surface area involvement, palmoplantar,
facial, genital involvement, or severe scalp psoriasis
-AND-
ii. History of failure to one of the following topical therapies, unless
contraindicated or clinically significant adverse effects are experienced
(document drug, date, and duration of trial):
a. Corticosteroids (e.g., betamethasone, clobetasol, desonide)
b. Vitamin D analogs (e.g., calcitriol, calcipotriene)
c. Tazarotene
d. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
e. Anthralin
f. Coal tar
© 2024 UnitedHealthcare Services, Inc.
1
-AND-
iii. History of failure to a 3 month trial of methotrexate at maximally
indicated dose, unless contraindicated or clinically significant adverse
effects are experienced (document date and duration of trial)b
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of plaque psoriasis as documented by claims
history or submission of medical records (Document drug, date, and duration
of therapy) [e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast),
Skyrizi (risankizumab), Stelara (ustekinumab), Tremfya (guselkumab),
Enbrel (etanercept)].
-OR-
(c) Both of the following:
i. Patient is currently on Cosentyx therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in
prescriber office, or any form of assistance from the Novartis sponsored
Cosentyx Connect (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Cosentyx*
-AND-
(3) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara
(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Taltz
(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
-AND-
(4) Prescribed by or in consultation with a dermatologist
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from the Novartis sponsored Cosentyx Connect shall be required to meet initial authorization
criteria as if patient were new to therapy.
© 2024 UnitedHealthcare Services, Inc.
2
Authorization will be issued for 12 months.
2. Reauthorization
a. Cosentyx will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Cosentyx therapy
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara
(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Taltz
(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
B. Psoriatic Arthritis (PsA)
1. Initial Authorization
a. Cosentyx will be approved based on all of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(2) One of the following:
(a) History of failure to a 3 month trial of methotrexate at maximally indicated
dose, unless contraindicated or clinically significant adverse effects are
experienced (document date and duration of trial)b
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of psoriatic arthritis as documented by claims
history or submission of medical records (Document drug, date, and duration
of therapy) [e.g., Cimzia (certolizumab), adalimumab, Simponi
(golimumab), Stelara (ustekinumab), Tremfya (guselkumab),
Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi
(risankizumab), Rinvoq (upadacitinib), Enbrel (etanercept)]
-OR-
(c) Both of the following:
© 2024 UnitedHealthcare Services, Inc.
3
i. Patient is currently on Cosentyx therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy)
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in
prescriber office, or any form of assistance from the Novartis sponsored
Cosentyx Connect (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Cosentyx*
-AND-
(3) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara
(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Taltz
(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
-AND-
(4) Prescribed by or in consultation with one of the following:
(a) Rheumatologist
(b) Dermatologist
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from the Novartis sponsored Cosentyx Connect shall be required to meet initial authorization
criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Cosentyx will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Cosentyx therapy
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara
(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Taltz
(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
© 2024 UnitedHealthcare Services, Inc.
4
Authorization will be issued for 12 months.
C. Ankylosing Spondylitis (AS)
1. Initial Authorization
a. Cosentyx will be approved based on all of the following criteria:
(1) Diagnosis of active ankylosing spondylitis
-AND-
(2) One of the following:
(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally
indicated doses, each used for at least 4 weeks, unless contraindicated or
clinically significant adverse effects are experienced (document drug, date,
and duration of trials)
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of ankylosing spondylitis as documented by
claims history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., adalimumab, Simponi (golimumab),
Xeljanz/Xeljanz XR (tofacitinib), Rinvoq (upadacitinib), Enbrel
(etanercept)].
-OR-
(c) Both of the following:
i. Patient is currently on Cosentyx therapy as documented by claims history
or submission medical records (Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in
prescriber office, or any form of assistance from the Novartis sponsored
Cosentyx Connect (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Cosentyx*
-AND-
(3) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
© 2024 UnitedHealthcare Services, Inc.
5
-AND-
(4) Prescribed by or in consultation with a rheumatologist
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from the Novartis sponsored Cosentyx Connect shall be required to meet initial authorization
criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Cosentyx will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Cosentyx therapy
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
D. Non-radiographic Axial Spondyloarthritis
1. Initial Authorization
a. Cosentyx will be approved based on all of the following criteria:
(1) Diagnosis of active non-radiographic axial spondyloarthritis
-AND-
(2) One of the following:
(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally
indicated doses, each used for at least 4 weeks, unless contraindicated or
clinically significant adverse effects are experienced (document drug, date,
and duration of trials)
-OR-
(b) Patient has been previously treated with a targeted immunomodulator
FDA-approved for the treatment of non-radiographic axial
spondyloarthritis as documented by claims history or submission of
© 2024 UnitedHealthcare Services, Inc.
6
medical records (Document drug, date, and duration of therapy) [e.g.,
Cimzia (certolizumab), Rinvoq (upadacitinib)]
-OR-
(c) Both of the following:
i. Patient is currently on Cosentyx therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy)
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in
prescriber office, or any form of assistance from the Novartis sponsored
Cosentyx Connect (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Cosentyx*
-AND-
(3) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
-AND-
(4) Prescribed by or in consultation with a rheumatologist
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from the Novartis sponsored Cosentyx Connect shall be required to meet initial authorization
criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Cosentyx will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Cosentyx therapy
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
© 2024 UnitedHealthcare Services, Inc.
7
Authorization will be issued for 12 months.
E. Enthesitis-Related Arthritis
1. Initial Authorization
a. Cosentyx will be approved based on all of the following criteria:
(1) Diagnosis of active enthesitis-related arthritis
-AND-
(2) One of the following:
(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally
indicated doses, each used for at least 4 weeks, unless contraindicated or
clinically significant adverse effects are experienced (document drug, date,
and duration of trials)
-OR-
(b) Both of the following:
i. Patient is currently on Cosentyx therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy)
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in
prescriber office, or any form of assistance from the Novartis sponsored
Cosentyx Connect (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Cosentyx*
-AND-
(3) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), adalimumab, Cimzia
(certolizumab), Simponi (golimumab), Xeljanz (tofacitinib), Rinvoq
(upadacitinib)]
-AND-
(4) Prescribed by or in consultation with a rheumatologist
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from the Novartis sponsored Cosentyx Connect shall be required to meet initial authorization
criteria as if patient were new to therapy.
© 2024 UnitedHealthcare Services, Inc.
8
Authorization will be issued for 12 months.
2. Reauthorization
a. Cosentyx will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Cosentyx therapy
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), adalimumab, Cimzia
(certolizumab), Simponi (golimumab), Xeljanz (tofacitinib), Rinvoq
(upadacitinib)]
Authorization will be issued for 12 months.
F. Hidradenitis Suppurativa (HS)
1. Initial Authorization
a. Cosentyx will be approved based on all of the following criteria:
(1) Diagnosis of moderate to severe hidradenitis suppurativa (i.e., Hurley Stage
II or III)
-AND-
(2) One of the following:
(a) History of failure to at least one oral antibiotic (e.g., doxycycline,
clindamycin, rifampin) at maximally indicated doses, unless contraindicated
or clinically significant adverse effects are experienced (document drug,
date, and duration of trial)
-OR-
(b) Both of the following:
i. Patient is currently on Cosentyx therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a Novartis sponsored
program (e.g., sample card which can be redeemed at a pharmacy for a
© 2024 UnitedHealthcare Services, Inc.
9
free supply of medication) as a means to establish as a current user of
Cosentyx*
-AND-
(3) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
-AND-
(4) Prescribed by or in consultation with a dermatologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from a Novartis sponsored program shall be required to meet initial
authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Cosentyx will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Cosentyx therapy.
-AND-
(2) Patient is not receiving Cosentyx in combination with another targeted
immunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia
(certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
© 2024 UnitedHealthcare Services, Inc.
10
4. Reference:
1. Cosentyx [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; October 2023.
2. Ward MM, Deodhar, A, Gensler, LS, et al. 2019 Update of the American College of
Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment
Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic
Axial Spondyloarthritis. Arthritis & Rheumatology. 2019; 71(10): 1599-1613.
3. Yu, DT, van Tubergen A. Treatment of axial spondyloarthritis (ankylosing spondylitis and
nonradiographic axial spondyloarthritis) in adults. Sieper, J (Ed). UpToDate. Waltham, MA:
UpToDate Inc. http://www.uptodate.com (Accessed on October 10, 2019.)
4. Singh, JA, Guyatt, G, et al. 2018 American College of Rheumatology/National Psoriasis
Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis & Rheumatology. 2019;
71(1): 5-32.
5. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of
psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.
6. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an
emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.
7. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis
with topical therapies. J Am Acad Dermatol 2009;60(4):643-59.
8. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and
photochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.
9. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with
traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.
10. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris – update
2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm Venereol
2015;29:2277-94.
11. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for
the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment
of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J
Am Acad Dermatol. 2011 Jul;65(1):137-74.
12. Gossec L, et al; European League Against Rheumatism (EULAR) recommendations for the
management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis
2016;75:499-510.
13. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management
and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.
14. Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a
favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week
results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol.
2021;35(4):938-947. doi:10.1111/jdv.17002
Program Prior Authorization/Medical Necessity - Cosentyx (secukinumab)
Change Control
5/2020 New program.
© 2024 UnitedHealthcare Services, Inc.
11
7/2020 Updated background and criteria to include new indication for non-
radiographic axial spondyloarthritis. Clarified documentation
requirements. Updated references.
11/2020 Added Tremfya as a step therapy medication for psoriatic arthritis.
Revised psoriasis step therapy medications due to expanded indication
for use of Stelara in patients 6 years and older.
6/2021 Removed prescriber requirement from reauthorization criteria. Added
coverage criteria for patients previously treated with a biologic
DMARD. Added clarification that submission of medical records is
required documenting current therapy with Cosenyx in order to bypass
step if claim history not available.
7/2021 Updated background to include expanded indication for moderate to
severe plaque psoriasis to pediatric patients 6 years and older. Updated
references.
12/2021 Updated the following with no change to clinical intent: updated
conventional DMARD bypass language for psoriatic arthritis and
psoriasis, removed “biologic” from required preferred product criteria
language, updated age requirement language and updated CT/KY
footnote.
2/2022 Updated background and clinical criteria with new indication for ERA.
Updated formatting of clinical criteria for nr-axSpA. Updated
reference.
3/2022 Added Skyrizi as a preferred drug for active psoriatic arthritis.
Clarified criteria for non-radiographic axial spondyloarthritis that
patient must still have a history of failure, contraindication, or
intolerance to Cimzia (certolizumab) whether they were previously
treated with a DMARD or have failed two NSAIDs.
6/2022 Added Rinvoq and Xeljanz to step therapy medication for ankylosing
spondylitis and psoriatic arthritis. Added Rinvoq and/or Xeljanz to
examples where appropriate. Added Mississippi to state mandate
footnote.
11/2022 Added Enbrel as a preferred product step option for AS, PsO, and PsA.
Added Enbrel as an example where appropriate. Added Rinvoq as a
step option for non-radiographic axial spondyloarthritis. Added targeted
synthetic to DMARD bypass for non-radiographic axial
spondyloarthritis.
1/2023 Updated step therapy requirements to Humira or Amjevita. Updated
listed examples from Humira to adalimumab.
4/2023 Updated step therapy requirement from Humira or Amjevita to one of
the preferred adalimumab products and added the footnote “For a list of
preferred adalimumab products please reference drug coverage tools.”
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
1/2024 Added coverage criteria for new indication for Hidradenitis Suppurativa
(HS). Updated state mandate footnote. Updated background and
reference.
10/2024 Removed all step therapy requirements through preferred products.
Removed adalimumab footnote.
© 2024 UnitedHealthcare Services, Inc.
12